CNS
- Ref-No.Technology
- 01-00986
Non-invasive and high-throughput monitoring of exon-specific isoform expression
- 01-00987
DMD Gene Therapy Approach
- 01-01015
AAV-based split-dCas9 gene activator system for in vivo reprogramming approaches
- 01-01045
Ex vivo method for determination of oxidative stress and diagnosis of ferroptosis-associated diseases
- 03-00363
Small molecule inhibitors of STOML3 promise to treat neuropathic pain
- 03-00367Targeting of Autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer’s and vascular dementia
- 03-00466
Selective iNOS small molecule inhibitors for the prevention of NO-dependent neuroinflammation
- 03-00471
A FRET-based method to measure seeding activity of misfolded protein species in complex biological samples
- 03-00493Novel Self-Organizing 3D Human Neuromuscular Organoids
- 10-00107Barnesins – novel natural small molecules as highly specific cysteine protease inhibitors
- 11-00057Innovative Nerve Sheath Tumor Therapy
- 15-00247
Methylation biomarker to predict the response to monoaminergic antidepressants
- 21-00011
Radiopharmaceutical for low-cost and high-sensitivity diagnosis of early-stage dementia and tissue viability in acute stroke.
- 21-00019
Microelectrode array with combined optical stimulation
- 21-00027
Ferulic acid derivatives as efficient neuroprotective agent and memory enhancer
- 23-00054
PDE1 as target for disease modifying therapy of multiple system atrophy (MSA) and other synucleinopathies
- 23-00064Treating dementia and other brain disorders with natural glycans
- 23-00065Novel treatment of dementia-associated tauopathies
- 23-00069
NMDAR targeted CAAR-T cell therapy
- 23-00074Treating C9orf72 ALS/FTD with active vaccination
- 23-00075
HERV inhibitors for use in tauopathies
- 43-00006Genetically engineered human 3D brain tumor models for disease modeling and compound evaluation